1. Home
  2. RLAY vs PAHC Comparison

RLAY vs PAHC Comparison

Compare RLAY & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLAY
  • PAHC
  • Stock Information
  • Founded
  • RLAY 2015
  • PAHC 1946
  • Country
  • RLAY United States
  • PAHC United States
  • Employees
  • RLAY N/A
  • PAHC N/A
  • Industry
  • RLAY Biotechnology: Biological Products (No Diagnostic Substances)
  • PAHC Biotechnology: Pharmaceutical Preparations
  • Sector
  • RLAY Health Care
  • PAHC Health Care
  • Exchange
  • RLAY Nasdaq
  • PAHC Nasdaq
  • Market Cap
  • RLAY 811.8M
  • PAHC 902.8M
  • IPO Year
  • RLAY 2020
  • PAHC 2014
  • Fundamental
  • Price
  • RLAY $3.92
  • PAHC $22.50
  • Analyst Decision
  • RLAY Strong Buy
  • PAHC Sell
  • Analyst Count
  • RLAY 10
  • PAHC 4
  • Target Price
  • RLAY $20.11
  • PAHC $21.00
  • AVG Volume (30 Days)
  • RLAY 1.4M
  • PAHC 265.5K
  • Earning Date
  • RLAY 02-28-2025
  • PAHC 02-05-2025
  • Dividend Yield
  • RLAY N/A
  • PAHC 2.13%
  • EPS Growth
  • RLAY N/A
  • PAHC 30.53
  • EPS
  • RLAY N/A
  • PAHC 0.48
  • Revenue
  • RLAY $10,006,000.00
  • PAHC $1,106,080,000.00
  • Revenue This Year
  • RLAY N/A
  • PAHC $28.33
  • Revenue Next Year
  • RLAY N/A
  • PAHC $10.57
  • P/E Ratio
  • RLAY N/A
  • PAHC $47.35
  • Revenue Growth
  • RLAY N/A
  • PAHC 12.63
  • 52 Week Low
  • RLAY $3.50
  • PAHC $11.99
  • 52 Week High
  • RLAY $10.89
  • PAHC $26.55
  • Technical
  • Relative Strength Index (RSI)
  • RLAY 41.60
  • PAHC 45.46
  • Support Level
  • RLAY $3.85
  • PAHC $24.33
  • Resistance Level
  • RLAY $4.19
  • PAHC $26.55
  • Average True Range (ATR)
  • RLAY 0.28
  • PAHC 1.29
  • MACD
  • RLAY -0.02
  • PAHC -0.15
  • Stochastic Oscillator
  • RLAY 24.80
  • PAHC 26.43

About RLAY Relay Therapeutics Inc.

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Share on Social Networks: